20 percent more patients were treated with proton therapy in 2019
An individual eye shield is made for each patient to protect the surrounding tissue from the proton beam. © HZB
Number of patients who received the proton therapy offered jointly by Charité and HZB. © HZB/J. Politt
For more than 20 years, Charité - Universitätsmedizin Berlin and the Helmholtz-Zentrum Berlin (HZB) have jointly offered the irradiation of eye tumors with protons. In 2019, more patients were treated in Berlin-Wannsee than ever before. 276 patients - 20 percent more than in the previous year - underwent proton therapy. The treatment is specialized in choroidal melanomas of the eye. The proton accelerator at HZB is the only treatment facility for this disease in Germany.
500 to 600 people in Germany are affected by a malignant choroidal melanoma every year. In 97 percent of cases, the tumour can be completely destroyed by irradiation with protons. In most cases, not only the eye but also the vision can be maintained to a satisfactory degree. "The energy of the proton beam can be adjusted in such a way that practically only the tumor receives the radiation. Since the protons have a straight trajectory, the lateral scattering is much less than with X-rays," explains Dr. Jens Heufelder, the senior medical physicist at Charité - Universitätsmedizin Berlin. The protons effectively destroy the tumor, while the surrounding healthy tissue is largely spared.
To cope with the increase in patients in 2019, treatment operations at the proton accelerator have been extended to 12 hours. Approximately 45 percent of the patients came from the Berlin-Brandenburg region, the other patients came from other German states and other European countries (approximately 8 percent). The youngest patient who received proton therapy at HZB in 2019 was 8 years old, the oldest patient 96 years old. The average age was 61 years.
Since 1998, more than 3,700 patients have been treated with protons from the HZB accelerator. "The success of proton therapy is based on the collaboration between ophthalmologists, medical physicists and accelerator experts. As a result, the therapy has been continuously improved for the benefit of patients over the past few years", explains Prof. Dr. Andrea Denker, head of proton therapy at HZB.
- Michael Naguib is visiting HZB as a Humboldt Research AwardeeProfessor Michael Naguib, from Tulane University in the USA, is one of the discoverers of a new class of 2D materials: MXenes are characterised by a puff pastry-like structure and have many applications, such as in the production of green hydrogen or as storage media for electrical energy. During his Humboldt Research Award in 2025, Professor Naguib is working with Prof Volker Presser at the Leibniz Institute for New Materials in Saarbrücken and with Dr Tristan Petit at HZB.
- AI in Chemistry: Study Highlights Strengths and WeaknessesHow well does artificial intelligence perform compared to human experts? A research team at HIPOLE Jena set out to answer this question in the field of chemistry. Using a newly developed evaluation method called “ChemBench,” the researchers compared the performance of modern language models such as GPT-4 with that of experienced chemists.
- TH Wildau and Helmholtz Zentrum Berlin signed comprehensive cooperationOn 21 May 2025, the Technical University of Applied Sciences Wildau (TH Wildau) and the Helmholtz-Zentrum Berlin für Materialien und Energie (HZB), signed a comprehensive cooperation agreement. The aim is to further promote networking and cooperation, particularly in basic research, to increase the scientific excellence of both partners and to develop competence networks in research, teaching and the training of young scientists.